Tempus AI (NASDAQ:TEM) Upgraded to “Hold” at Freedom Capital

Tempus AI (NASDAQ:TEM) was upgraded by investment analysts at Freedom Capital to a “hold” rating in a research report issued on Tuesday,Zacks.com reports.

A number of other equities research analysts have also recently issued reports on TEM. BTIG Research reaffirmed a “buy” rating and set a $80.00 target price on shares of Tempus AI in a research report on Monday, June 1st. HC Wainwright decreased their target price on Tempus AI from $95.00 to $64.00 and set a “buy” rating on the stock in a research report on Monday, May 11th. Needham & Company LLC reissued a “buy” rating and issued a $75.00 price target on shares of Tempus AI in a report on Monday, June 1st. Jefferies Financial Group began coverage on Tempus AI in a report on Monday, April 13th. They issued an “underperform” rating and a $35.00 target price for the company. Finally, TD Cowen lifted their price target on shares of Tempus AI from $65.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Nine research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Tempus AI presently has an average rating of “Hold” and an average price target of $68.54.

Tempus AI Price Performance

TEM opened at $61.60 on Tuesday. Tempus AI has a 1 year low of $41.73 and a 1 year high of $104.32. The stock has a fifty day moving average price of $50.28 and a 200 day moving average price of $54.60. The company has a current ratio of 3.31, a quick ratio of 3.15 and a debt-to-equity ratio of 2.96. The stock has a market cap of $11.06 billion, a price-to-earnings ratio of -35.81 and a beta of 3.45.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. The firm had revenue of $348.12 million for the quarter, compared to the consensus estimate of $345.44 million. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The firm’s revenue was up 36.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.24) earnings per share. Analysts forecast that Tempus AI will post -1.35 EPS for the current fiscal year.

Insider Activity at Tempus AI

In other news, CEO Ryan Fukushima sold 13,550 shares of the firm’s stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total value of $597,148.50. Following the transaction, the chief executive officer owned 603,558 shares of the company’s stock, valued at approximately $26,598,801.06. This trade represents a 2.20% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Eric P. Lefkofsky sold 166,250 shares of the firm’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $46.70, for a total transaction of $7,763,875.00. Following the completion of the transaction, the chief executive officer directly owned 8,808,533 shares in the company, valued at approximately $411,358,491.10. The trade was a 1.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 572,759 shares of company stock worth $29,238,424. Insiders own 24.26% of the company’s stock.

Hedge Funds Weigh In On Tempus AI

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. NewEdge Advisors LLC lifted its holdings in Tempus AI by 1.3% during the first quarter. NewEdge Advisors LLC now owns 42,996 shares of the company’s stock worth $1,944,000 after acquiring an additional 536 shares in the last quarter. Avidity Partners Management LP bought a new stake in shares of Tempus AI in the first quarter valued at about $1,130,000. Silverback Asset Management LLC boosted its position in shares of Tempus AI by 44.5% during the first quarter. Silverback Asset Management LLC now owns 35,700 shares of the company’s stock worth $1,614,000 after buying an additional 11,000 shares during the period. Vestor Capital LLC grew its holdings in shares of Tempus AI by 338.2% during the first quarter. Vestor Capital LLC now owns 1,538 shares of the company’s stock worth $70,000 after buying an additional 1,187 shares in the last quarter. Finally, Arkadios Wealth Advisors grew its holdings in shares of Tempus AI by 9.6% during the first quarter. Arkadios Wealth Advisors now owns 4,963 shares of the company’s stock worth $224,000 after buying an additional 435 shares in the last quarter. 24.22% of the stock is owned by institutional investors.

Key Headlines Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Analyst-style coverage argued Tempus AI remains attractive because of diagnostics momentum, AI platform expansion, and recent FDA-related product gains that may broaden future growth. Tempus AI: Buy On Diagnostics Momentum And AI Platform Expansion
• Positive Sentiment: Some market commentary suggested the recent pullback may be creating a buying opportunity for investors who believe in Tempus AI’s long-term growth story. Tempus AI stock faces a make-or-break moment after its recent pullback
• Neutral Sentiment: Konica Minolta completed the sale of Tempus shares it previously received, which may remove a supply overhang but is not an operating update. Konica Minolta Completes Sale of Tempus Shares to Bolster Balance Sheet
• Negative Sentiment: Biovica said it is refocusing its U.S. commercial strategy and terminating its agreement with Tempus AI, which could reduce a partnership-related opportunity. Biovica Refocuses US Commercial Strategy and Terminates Agreement with Tempus AI
• Negative Sentiment: Recent insider selling by the CFO, CEO, and a director may be pressuring sentiment, even though the trades were made under pre-arranged plans. Tempus AI CEO insider sale filing

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.